However, NRAS mutations in JMML are often associated with higher relapse rates, warranting adjusted post-transplant treatment strategies, including low-intensity graft versus host disease (GVHD) prophylaxis to enhance the graft versus leukemia (GVL) effect and reduce the risk of relapse. The gene discussed is NRAS; the disease is leukemia.